MIA awarded prestigious NHMRC grant
The NHMRC grant will enable MIA to lead an international clinical trial aiming to safely reduce surgery for high risk Stage III melanoma patients who have had a good response to neoadjuvant immunotherapy.
Addressing fear of cancer recurrence
A study has been released investigating the effectiveness of a Melanoma Care Program for patients with early-stage melanoma with varying degrees of fear of cancer recurrence after treatment of their primary melanoma.
Global accuracy of MIA risk tool predicting sentinel node metastasis
The extensive global use of MIA’s online tool for estimating the risk of nodal metastasis in newly diagnosed melanoma patients has prompted an international study to validate its accuracy & improve its precision across diverse populations worldwide.
Leading MIA researchers and clinicians share latest advances in Athens
MIA researchers and clinicians attended the World Congress of Melanoma, held in conjunction with the EADO Congress, in Athens.
Early career fellowship for Dr Rebecca Simpson
MIA researcher Dr Rebecca Simpson has been awarded a CINSW 2024 Early Career Fellowship which supports early & mid-career researchers through the development of research & leadership skills & innovative approaches to research.
First step to develop Roadmap for Targeted Skin Cancer Screening Program
We are excited to commence the work to develop the Roadmap for a National Targeted Skin Cancer Screening Program, and proud to be leading such an important endeavour for the Australian community.
Roadmap for a National Targeted Skin Cancer Screening Program
Skin checks are an important tool in the early detection of skin cancers. MIA & others in the skin cancer community have advocated for a more systematic, targeted & equitable approach to skin cancer screening in Australia. As a result, the Australian Gov't has allocated $10m for development of a Roadmap for a National Targeted Skin Cancer Screening Program.
From just 16 weeks’ survival to long term disease control
Newly released long-term data from a groundbreaking clinical trial for advanced melanoma patients whose disease had spread to their brain has proven that long-term disease control has been achieved for over 50% of patients given combination immunotherapy as first line treatment.
MIA’s ground-breaking work recognised with two Cancer NSW Awards
We are proud to announce that the ground-breaking work of the MIA team has been recognised with two prestigious 2024 NSW Premier’s Awards for Outstanding Cancer Research.
Be part of research study on genetic information and testing
Patients, and families of patients, impacted by advanced melanoma are invited to participate in an online interview to explore their views, experiences, and needs related to genetic information, support and testing.